Free Trial
NASDAQ:ANIP

ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis

ANI Pharmaceuticals logo
$66.33 +0.35 (+0.53%)
Closing price 03/25/2025 04:00 PM Eastern
Extended Trading
$68.66 +2.33 (+3.51%)
As of 03/25/2025 06:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About ANI Pharmaceuticals Stock (NASDAQ:ANIP)

Key Stats

Today's Range
$64.74
$68.13
50-Day Range
$54.51
$66.33
52-Week Range
$52.50
$70.31
Volume
536,707 shs
Average Volume
243,535 shs
Market Capitalization
$1.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$79.75
Consensus Rating
Buy

Company Overview

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Remove Ads

ANI Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

ANIP MarketRank™: 

ANI Pharmaceuticals scored higher than 72% of companies evaluated by MarketBeat, and ranked 293rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    ANI Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

  • Read more about ANI Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for ANI Pharmaceuticals are expected to grow by 9.07% in the coming year, from $3.86 to $4.21 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ANI Pharmaceuticals is -120.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ANI Pharmaceuticals is -120.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ANI Pharmaceuticals has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about ANI Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    13.94% of the float of ANI Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    ANI Pharmaceuticals has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.
  • Change versus previous month

  • Dividend Yield

    ANI Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    ANI Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.94% of the float of ANI Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    ANI Pharmaceuticals has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.
  • Change versus previous month

  • News Sentiment

    ANI Pharmaceuticals has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for ANI Pharmaceuticals this week, compared to 5 articles on an average week.
  • Search Interest

    7 people have searched for ANIP on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $191,776.00 in company stock.

  • Percentage Held by Insiders

    12.70% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ANI Pharmaceuticals' insider trading history.
Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANIP Stock News Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
ANI Pharmaceuticals launches Nitazoxanide Tablets, 500 mg.
See More Headlines

ANIP Stock Analysis - Frequently Asked Questions

ANI Pharmaceuticals' stock was trading at $55.28 on January 1st, 2025. Since then, ANIP stock has increased by 20.0% and is now trading at $66.33.
View the best growth stocks for 2025 here
.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) posted its quarterly earnings data on Friday, November, 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.25. The firm's revenue for the quarter was up 12.5% on a year-over-year basis.

ANI Pharmaceuticals' top institutional investors include Vanguard Group Inc. (6.25%), Millennium Management LLC (4.77%), Dimensional Fund Advisors LP (3.26%) and Deep Track Capital LP (3.09%). Insiders that own company stock include Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Chad Gassert, Stephen P Carey, James G Marken, Christopher Mutz, Meredith Cook, Ori Gutwerg, Krista Davis, Antonio R Pera and Renee P Tannenbaum.
View institutional ownership trends
.

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ANI Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

Last Earnings
11/08/2024
Today
3/25/2025
Next Earnings (Estimated)
5/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ANIP
Previous Symbol
NASDAQ:BPAX
Employees
600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$79.75
High Stock Price Target
$94.00
Low Stock Price Target
$62.00
Potential Upside/Downside
+20.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
17.18
P/E Growth
N/A
Net Income
$18.78 million
Pretax Margin
-1.35%

Debt

Sales & Book Value

Annual Sales
$614.38 million
Cash Flow
$7.35 per share
Price / Cash Flow
9.03
Book Value
$21.13 per share
Price / Book
3.14

Miscellaneous

Free Float
18,358,000
Market Cap
$1.44 billion
Optionable
Optionable
Beta
0.63

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ANIP) was last updated on 3/26/2025 by MarketBeat.com Staff
From Our Partners